MediWound Ltd. (MDWD) Stock Analysis

MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ...

Thu, August 13, 2026 at 11:07 PM UTC 2 min read

MediWound Ltd (MDWD) reported record sales for its products NexoBrid and EscharEx during the Q2 2026 earnings call, highlighting strong demand and market penetration. This performance underscores the company's growth potential and effectiveness in addressing wound care needs, which could positively impact future revenue streams. Investors may view this as a sign of robust operational execution and a solid foundation for continued expansion in the healthcare sector.

Read full article →

MediWound to Report Second Quarter 2026 Financial Results

Wed, July 29, 2026 at 12:00 PM UTC 2 min read

MediWound (MDWD) is set to report its financial results for the second quarter of 2026, providing investors with insights into the company's performance and growth trajectory. This announcement is significant as it will likely influence investor sentiment and expectations regarding MediWound's product pipeline and market positioning. Investors should closely monitor the results for any updates on revenue, expenses, and strategic initiatives that could impact future stock performance.

Read full article →